Ahmed Alanazi, Department Program Director at King Fahad Medical City, shared a post on X:
“EMBER3 updates subgroups
Co mutation of PIK3CA/ESR1? and prior CDK4/6
Is Combo better than SERDs alone? Subgroups and low number of patients?
Combo showed more benefit! But >60% received palbociclib as prior CDK4/6i”
EMBER-3 Trial Updates from ESMO Breast 2025
